The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Non-HDL-cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population
Open accessAbstract
BACKGROUND: Our objective was to evaluate the accuracy of cardiovascular disease (CVD) risk score classification by direct LDL cholesterol (dLDL-C), calculated LDL cholesterol (cLDL-C), and non–HDL cholesterol (non–HDL-C) compared to classification by reference measurement procedures (RMPs) performed at the CDC. METHODS: We examined 175 individuals, including 138 with CVD or conditions that may affect LDL-C measurement. dLDL-C measurements were performed using Denka, Kyowa, Sekisui, Serotec, Sysmex, UMA, and Wako reagents. cLDL-C was calculated by the Friedewald equation, using each manufacturer's direct HDL-C assay measurements, and total cholesterol and triglyceride measurements by Roche and Siemens (Advia) assays, respectively. RESULTS: For participants with triglycerides <2.26 mmol/L (<200 mg/dL), the overall misclassification rate for the CVD risk score ranged from 5% to 17% for cLDL-C methods and 8% to 26% for dLDL-C methods when compared to the RMP. Only Wako dLDL-C had fewer misclassifications than its corresponding cLDL-C method (8% vs 17%; P < 0.05). Non–HDL-C assays misclassified fewer patients than dLDL-C for 4 of 8 methods (P < 0.05). For participants with triglycerides ≥2.26 mmol/L (≥200 mg/dL) and <4.52 mmol/L (<400 mg/dL), dLDL-C methods, in general, performed better than cLDL-C methods, and non–HDL-C methods showed better correspondence to the RMP for CVD risk score than either dLDL-C or cLDL-C methods. CONCLUSIONS: Except for hypertriglyceridemic individuals, 7 of 8 dLDL-C methods failed to show improved CVD risk score classification over the corresponding cLDL-C methods. Non–HDL-C showed overall the best concordance with the RMP for CVD risk score classification of both normal and hypertriglyceridemic individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Despite this limitation, non-HDLC yields more accurate cardiovascular risk classification than either Friedewald cLDLC or dLDLC, and also more consistent risk scores using different manufacturers' assays for dHDLC in the calculation [58].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [58]
In the citing paper
“As a result, under most circumstances, they provide very similar information about ASCVD risk [45,105-108].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [107]
In the citing paper
“In general, LDL-C, non-HDL-C, and ApoB concentrations are very highly correlated.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., Hulley, S. B., Kagan, A., & Zukel, W. J. (1977) · Circulation · doi:10.1161/01.cir.55.5.767 · Cited by 1,492
Current databases on biological variation: pros, cons and progress
C. Ricós, V. A. (1999) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365519950185229 · Cited by 987
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 716
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Flagged first, then by citations
Research works printed but not linked: 1
- Nauck, 2000, Measurement of high-density-lipoprotein cholesterol, 227
Cited by
Sorted by citations
Items 101–112 of 112
Ramírez, J. C. V., Rodríguez‐García, E., Romero, C., Estébanez, B. C., Castro, M. J. C., Velilla, T. A., Calmarza, P., Salán, M. E., Mieras, M. P., & Puzo, J. (2018) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2018.08.002 · Cited by 1
Malara, M., Widłak, P., & Lutosławska, G. (2023) · Medical Research Journal · doi:10.5603/mrj.96741 · Cited by 1
Klinische Befunde und rationelle Differenzialdiagnostik der diabetischen Dyslipidämie
von Eckardstein, A. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0890-5
Mizuno, K., Nakaya, N., Teramoto, T., Yokoyama, S., Ohashi, Y., Ueki, A., Takahashi, S., Kubota, Y., & Nakamura, H. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e1
HBA1C: IS IT READY AS A PRIMETIME TOOL FOR PREDICTING MYOCARDIAL INFARCTION?
Harish, R., Shashidhar, K., Lakshmaiah, V., & Mati, E. (2014) · Journal of Pharmaceutical and Scientific Innovation · doi:10.7897/2277-4572.034171
Al-Haideri, M. T. (2015) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2014.0037
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Measured LDL - an unnecessary expense or a customer service?
Simkins, A. (2013) · New Zealand journal of medical laboratory science
What Are the Goals of Lipid Testing?
Winter, W. E., Harris, N., & Flax, S. D. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.022939
Diabetes mellitus & disorders of lipid metabolism
Steinmetz, A. (2015) · doi:10.4155/fseb2013.14.200
APOE2 promotes longevity independent of Alzheimer’s diseasePreprint
Shinohara, M., Kanekiyo, T., Tachibana, M., Kurti, A., Shinohara, M., Fu, Y., Zhao, J., Han, X., Sullivan, P. M., Rebeck, W. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.31.255141
Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers
Li, L., Feng, Y., Li, X., Yu, Z., Sun, C., Hu, L., Zhou, K., Liu, X., Yuan, Y., Li, L., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1857230
Metadata
- Authors
- van Deventer, H. E., Miller, W. G., Myers, G. L., Sakurabayashi, I., Bachmann, L. M., Caudill, S. P., Dziekonski, A., Edwards, S., Kimberly, M. M., Korzun, W. J., Leary, E. T., Nakajima, K., Nakamura, M., Shamburek, R. D., Vetrovec, G. W., Warnick, G. R., & Remaley, A. T.
- Affiliations
- National Institutes of Health, Bethesda, MD
- Virginia Commonwealth University (US)
- Centers for Disease Control and Prevention (US)
- Jichi Medical University (JP)
- Virginia Commonwealth University, Richmond, VA
- Pacific Biomarkers (United States) (US)
- Otsuka (Japan) (JP)
- Osaka Medical Center for Health Science and Promotion, Osaka, Japan
- National Institutes of Health (US)
- Health Diagnostics Laboratory, Richmond, VA
- Corresponding author
- Remaley, Alan T
- ORCID
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 490-501
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- PMC
- PMC4684263
- OpenAlex
- W2158071129
- Cited by
- 112
- References
- 39
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 5 · 2021: 3 · 2020: 9 · 2019: 8 · 2018: 12 · 2017: 10 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 9
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Genzyme
- Pointe Scientific
- Pacific Biometrics Research Foundation provided
- Virginia Commonwealth University
- National Institutes of Health
- Warren Grant Magnuson Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-HDL cholesterol, LDL cholesterol, cardiovascular risk score, dyslipidemia, Friedewald formula, hypertriglyceridemia, assay comparison, reference measurement procedure, misclassification rate
- MeSH terms
- Blood Chemical Analysis, Cardiovascular Diseases, Data Interpretation, Statistical, Fasting, Humans, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Sensitivity and Specificity, Triglycerides, Ultracentrifugation, Reproducibility of Results, Case-Control Studies, Risk Assessment, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
